ARTICLE | Clinical News
Celgene reports detailed data from missed Phase III of Revlimid combo for follicular lymphoma
June 15, 2018 6:20 PM UTC
Celgene Corp. (NASDAQ:CELG) reported detailed data from the Phase III RELEVANCE trial of Revlimid lenalidomide plus Rituxan rituximab to treat previously untreated follicular lymphoma. The data were presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago.
Celgene previously reported that Revlimid plus Rituxan missed the co-primary endpoints of improving complete response/unconfirmed complete response rate at 120 weeks and progression-free survival (PFS), but did not disclose details (see BioCentury, Dec. 22, 2017)...
BCIQ Target Profiles